BRAF and skin basal cell carcinoma: BCC patients with BCC-associated STR somatic mutations in BRAF or APC show more marked overexpression of proteasome-related genes (see Figure 12), and so they may be better candidates for the potential use of drugs like bortezomib, carfilzomib, or ixazomib.